PE Deals

Warburg’s Ruoxi Chen: Innovative therapies will drive demand for Simtra BioPharma Solutions

Warburg Pincus and Advent International earlier this week completed the carve-out of Baxter International’s BPS business for $4.25bn.

-

To read this article, you need to sign in.

Sign In

You should only be asked to sign in once. Not the case? Click here

New to PE Hub?

Register now to read this article and more for free.

Register Now